Sanofi SNY and Roche RHHBY announced their fourth-quarter and full-year 2024 results. Novo Nordisk’s NVO novel obesity ...

With (almost) no fees and unlimited refunds for ATM charges, Novo business checking is a good option for small-business owners on the go. But Novo’s customer support is lacking, and you can’t ...

HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, according to a entry.

The approval is based on results from the Phase III FLOW trial demonstrating Ozempic reduced the risk of severe kidney outcomes by 24% compared to placebo, including kidney failure, reduction in ...

Infant mortality in the U.S. has increased by 7% since the 2022 Dobbs v. Jackson U.S. Supreme Court decision overturned the ...

Dr. Reddy's Lab is poised to witness crosswinds from a drop in revenue from the patent expiration of Revlimid and increased ...

The US Food and Drug Administration on Tuesday approved Ozempic for adults with type 2 diabetes and chronic kidney disease (CKD). The drug is now indicated specifically to treat kidney failure, ...

The Food and Drug Administration approved Novo Nordisk’s Ozempic as the first GLP-1 treatment option for people with type 2 ...

A popular diabetes drug just got a major new approval—and it could be a game-changer for millions of Americans at risk for ...